SciSparc's NeuroThera Launches Phase IIb Trial at Yale for Tourette Syndrome, Reveals 21% Tic Reduction in Prior Study
SPRC has more than doubled off its 52-week low of $2.98.
Summary
NeuroThera, SciSparc's majority-owned subsidiary, has opened a U.S. clinical trial site at the Yale Child Study Center for its Phase IIb study of SCI-110 in adults with Tourette Syndrome. This follows the July 15 initiation of a site in Germany and adds a prestigious U.S. center led by Dr. Michael H. Bloch. The company disclosed positive Phase IIa results showing an average 21% reduction in tics, providing a concrete efficacy signal. The Phase IIb trial is a randomized, double-blind, placebo-controlled, cross-over design with a primary endpoint of tic severity change at 12 and 26 weeks. With limited treatment options for adult TS, positive data could position SCI-110 as a first-of-its-kind therapy. The trial's expansion to Yale and the release of prior efficacy data are incremental but meaningful steps in the drug's development path.
At the time of this announcement, SPRC was trading at $7.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9M. The 52-week trading range was $2.98 to $80.10. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.